Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

PARP inhibitor olaparib slows progression of advanced prostate cancer

Prof Maha Hussain - Northwestern University Feinberg School of Medicine...

PARP inhibitor olaparib slows progression of advanced prostate cancer ( Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago, USA )

Role of biomarkers, targeted therapy and tumour mutations in the landscape of...

Prof Petros Grivas and Dr Michiel Van der Heijden

Role of biomarkers, targeted therapy and tumour mutations in the landscape of bladder cancer ( Prof Petros Grivas and Dr Michiel Van der Heijden )

Comment: PARP inhibitors for advanced prostate cancer

Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain

Comment: PARP inhibitors for advanced prostate cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )

Comment: Immunotherapy plus chemotherapy in bladder cancer

Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain

Comment: Immunotherapy plus chemotherapy in bladder cancer ( Dr Ignacio Duran - Hospital Universitario Virgen del Rocío, Sevilla, Spain )

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City...

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma ( Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA )

Atezolizumab added to chemotherapy prolongs progression free survival in...

Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain

Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer ( Dr Enrique Grande - Hospital MD Anderson Cancer Center Madrid, Madrid, Spain )

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

Comment: Targeted therapy ivosidenib in cholangiocarcinoma ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF...

Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer ( Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

Comment: Keynote 522 trial

Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy

Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in...

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California

CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )

More from ecancer